Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meda AB
Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Acton Pharmaceuticals, Inc.
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Madaus Pharma
- Rottapharm Madaus
- Meda Pharmaceuticals Inc.